Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy’s Three Dermatology Products

Shots:

• Encore through its subsidiary Promius Pharma, has acquired US commercialization rights for Sernivo spray (betamethasone dipropionate), Trianex (Triamcinolone Acetonide Ointment, USP) and Promiseb from Dr. Reddy
• The focus of the acquisition is to expand Encore’s portfolio of dermatology products for the treatment of skin diseases such as psoriasis, atopic dermatitis and acne
• Sernivo (betamethasone dipropionate) spray 0.05% is targeted to reduce the symptoms of mild-to-moderate plaque psoriasis, such as itching, flaking & redness. Trianex 0.005% is a corticosteroid ointment used to relief inflammatory and itching symptoms of corticosteroid-responsive skin diseases

Click here to read full press release/ article | Ref: Business Wire | Image: Twitter